. Mounting genetic and biochemical data support the hypothesis that amyloid-β (Aβ) accumulation and aggregation in the brain are early and central events in the pathogenesis of AD 2, 3 . Aβ is derived from sequential proteolytic processing of amyloid precursor protein (APP) by β-and γ-secretases. Mutations associated with early-onset familial AD (FAD) are dominantly inherited and are found in the APP gene itself or in the presenilin 1 (PSEN1) and PSEN2 genes, the products of which, together with nicastrin, APH1 and PSENEN2, are essential components of a protein complex that is responsible for γ-secretase activity 4 . A common feature of most FAD mutations is that they increase the generation of Aβ peptides or increase the proportion of the longer Aβ42 form, which has a higher tendency to aggregate and is more toxic than the shorter Aβ40 form 3 . Because γ-secretase cleavage of a number of substrates is important for synaptic function and neuronal survival, a loss-of-function hypothesis for PSEN mutations in AD pathogenesis has also been proposed 5 . FAD genetics and mouse models have shed light on early-onset AD pathogenesis, but the vast majority of AD cases occur late in life. The ε4 allele of the apolipoprotein E (APOE) gene is a major risk for late-onset AD (LOAD). This risk allele, which was discovered in 1993 by Strittmatter, Roses and colleagues 6, 7 , has been validated in numerous genetic association studies (see the AlzGene website). Although a gene on chromosome 19 had previously been implicated in LOAD risk, the observation that APOE binds to Aβ in the cerebrospinal fluid (CSF) prompted the testing of APOE as a positional candidate 6 . APOE is a major apolipoprotein and a cholesterol carrier in the brain 8 . In humans, the APOE gene exists as three different polymorphic alleles (ε2, ε3 and ε4), which engender six different genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4 and ε4/ε4). ε3 is the most (77%) and ε2 the least (8%) common allele 8 . The ε4 allele frequency is ~15% in general populations but is ∼40% in patients with AD. Individuals with one ε4 allele are three to four times as likely to develop AD than those without ε4 alleles 7, 9 . This odds ratio is much greater than those for other AD risk alleles, which are typically <1.5 (Ref. 9) . The effects of the ε4 allele on AD risk are maximal between 60 and 70 years of age 10 , and the prevalence of the ε4 allele in AD patients is >50% 7 . Interestingly, the rare ε2 allele is associated with protection against LOAD compared with the ε3 allele 7 . The ε4 allele is also a risk factor for atherosclerosis 8 , HIV disease progression 11 and additional neurological disorders including cerebral amyloid angiopathy (CAA) and CAA-associated cerebral haemorrhages 12 , tauopathies and dementia with Lewy bodies 13 , Parkinson's disease 14 and multiple sclerosis 15 . These observations suggest that the ε4 allele may be associated with accelerated neurodegeneration in the development and progression of several neurodegenerative diseases.
The three APOE isoforms (APOE2, APOE3 and APOE4) differ from each other by a single amino acid 8 . In most if not all putative AD pathogenic pathways, APOE4 either diminishes protection or augments toxicity when compared with APOE2 and APOE3. In the brain, APOE-lipoprotein particles are produced primarily by astrocytes and deliver cholesterol and other essential lipids to neurons through members of the lowdensity lipoprotein receptor (LDLR) family 16, 17 . Although the mechanisms that underlie the pathogenic nature of APOE4 in AD are still not completely understood, several pathways have been identified in vitro and in vivo. In this Review, I describe Aβ-dependent and Aβ-independent pathways through which APOE isoforms and APOE receptors contribute to AD pathogenesis, with particular attention to the distinct functions of the different APOE receptors and the recent advances and challenges in targeting APOE and APOE receptors for AD therapy.
Biochemical properties of APOE APOE is an ∼34 kDa protein that transports cholesterol and other lipids in the plasma and the CNS by binding to cell surface APOE receptors 8 . Its highest concentration is in the liver and the brain. In the periphery, APOE transports liver-synthesized very low density lipoprotein (VLDL), a subclass of high-density lipoprotein (HDL) and intestinally synthesized chylomicrons. In the brain, APOE is synthesized predominantly by astrocytes and to some extent by microglia 18, 19 . APOE-lipoprotein particles from human CSF are the size and density of plasma HDL, are spherical and contain a core lipid: esterified cholesterol 20, 21 . Interestingly, nascent APOE-lipoprotein particles secreted by cultured astrocytes are primarily discoid and contain little lipid 21 . It is possible that astrocyte-secreted APOE-lipoprotein particles acquire a core of esterified cholesterol before reaching the CSF. Alternatively, native APOE-lipoprotein particles produced by astrocytes in the brain may differ from those that are secreted by cultured astrocytes. For APOE to be stable in the brain it must associate with lipids, as evidenced by the marked reduction in brain APOE levels that occurs when the murine Abca1 gene, the product of which lipidates APOE, is deleted 22, 23 . Human APOE contains 299 amino acid residues and has independently folded amino-terminal and carboxy-terminal domains, which are joined together by a flexible hinge region 24, 25 (fIG. 1) . The region that interacts with APOE receptors (residues [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] is in the N-terminal domain, whereas the major lipid-binding region (residues 244-272) is in the C-terminal domain. The three isoforms, APOE2, APOE3 and APOE4, differ at positions 112 and 158 (Refs 8, 24, 26) . These single amino acid differences among the three APOE isoforms alter the protein's structure and influence its lipid association and receptor binding 24 . For example, APOE3 and APOE4 bind to LDLR with ∼50-fold greater affinity than APOE2. As a result, APOE2 transports lipids less efficiently, and its presence is associated with type III hyperlipoproteinaemia. APOE4 preferentially binds to large lipoprotein particles and is also associated with a modestly increased risk of cardiovascular disease. APOE4's preference for larger lipoprotein particles is attributable to the presence of Arg at position 112, which affects the conformation of the side chain of Arg61, resulting in 'domain inter action' between this Arg61 in the N-terminal domain and Glu255 in the C-terminal domain.
In all animal species except humans, APOE does not have genetic variants and contains Thr at the position that is equivalent to Arg61 in human APOE4. Therefore, with respect to domain interaction, APOE in other species functionally behaves like APOE3, regardless of whether it has an Arg at position 112 (Ref. 24) . Introducing an Arg residue at position 61 into murine APOE converted it to a human APOE4-like structure with domain interaction 27 . Human APOE4 and mouse Arg61 APOE are present at lower levels in the brain than other isoforms, suggesting that the domain interaction directly affects APOE's stability. APOE4 also assumes an unstable 'molten globule' state 24 . The unique properties of the domain interaction and the molten globule state underlie the pathogenic role of APOE4 in AD 24, 25 . APOE receptors: members of the LDLR family APOE binds primarily to a group of receptors known as the LDLR family 16, 17 . The prototype of this family is LDLR, which is the main receptor for cholesterol homeotasis 28, 29 . Loss-of-function mutations in the LDLR gene cause high plasma LDL levels, which lead to familial hypercholesterolaemia and atherosclerosis. LDLR binds both APOB-containing LDL and APOE-containing particles of different densities through electrostatic inter actions between the basic amino acid residues on APOB or APOE and the acidic residues on the receptor. In 1988, a 4,544-amino acid protein containing the signature complement-type repeats and epidermal growth factor (EGF) precursor homology domains of LDLR was cloned 30 (fIG. 2) . This protein, named LDLR-related protein (LRP, now commonly known as LRP1 to distinguish it from other LRPs), is highly expressed in the liver and brain and binds more than 30 ligands, including APOE, α 2 -macroglobulin, tissue-type plasminogen activator and APP. LRP1 is synthesized as a single glycosylated protein (of ∼600 kDa) and then cleaved by furin in the trans-Golgi network to generate a 515 kDa extracellular subunit and an 85 kDa transmembrane subunit, which remain non-covalently associated with one another 31 . LRP1 is subjected to additional proteolysis that resembles APP-Notch processing
. Like LDLR, LRP1 . Brain-specific knockout of the Lrp1 gene demonstrates that LRP1 has important roles in synaptic transmission and motor function in the CNS 34 . The 100-amino acid cytoplasmic tail of LRP1 binds to various adaptor proteins that function in receptor trafficking and signalling 16 . Over ten receptors have now been identified as members of the LDLR family; they all contain characteristic ligand-binding repeats, EGF-like repeats and β-propeller-like structures with ywTD motifs (fIG. 2) . These receptors bind a diverse array of ligands, including APOE, to mediate their transport and/or signalling (see Supplementary information S1 (table)). In addition to LRP1, this family includes two other ∼600 kDa receptors, megalin (also known as LRP2) and LRP1B. Megalin is expressed abundantly on the apical surface of the epithelial cells of the proximal tubules in the kidney and functions in ligand resorption 35 . LRP1B is a putative tumour suppressor that is highly homologous to LRP1 (59% identity at the amino acid level), and the two have overlapping ligand binding 36 . However, because of its slow rate of endocytosis 36 , LRP1B antagonizes LRP1 function in ligand uptake 37, 38 . VLDL receptor (VLDLR) and APOE receptor 2 (APOER2; also known as LRP8) are structurally similar to LDLR, but instead of functioning as typical endocytic receptors they primarily serve as reelin signalling receptors 39 . Multiple EGF-like domain 7 (MEGF7; also known as LRP4) structurally resembles a portion of LRP1 and functions in limb patterning 40 and in neuromuscular synapse formation by serving as a receptor for agrin 41 . Sortilin-related receptor with A-type repeats (SORLA; also known as SORL1 and LR11), LRP5 and LRP6 are structurally more diverse than the core members of the LDLR family described above. whereas SORLA functions primarily in intracellular protein trafficking, LRP5 and LRP6 are co-receptors for canonical wnt-β-catenin signalling 42 . Several of these LDLR family members have important roles in neuronal development and synaptic plasticity 17, 43 . All members of the LDLR family bind APOE and receptor-associated protein (RAP; also known as LRPAP1), a molecular chaperone that promotes receptor folding and maturation in the secretory pathway 44 . RAP also universally antagonizes ligand binding to LDLR family members 44, 45 .
Metabolic APOE-lipoprotein receptors in the brain LDLR and LRP1 are the main APOE -lipoprotein metabolic receptors in the brain. Deletion of the Ldlr gene in mice increases APOE levels in the brain parenchyma and CSF 46 , suggesting that it causes impaired metabolism of APOE. Similarly, conditional deletion of the Lrp1 gene in mouse forebrain neurons increases APOE levels 47 , whereas overexpression of a functional LRP1 minireceptor in the mouse brain decreases brain APOE levels 48 . Although both LDLR and LRP1 have roles in brain APOE-lipoprotein metabolism, there are important differences between these roles. First, whereas LRP1 is expressed highly in neurons and to a lesser degree in glia, LDLR is more prominently expressed in glia than in neurons 49, 50 . Second, deletion of the Lrp1 gene in mouse forebrain neurons reduces brain cholesterol levels 47 , whereas cholesterol levels in Ldlr-knockout mice are unchanged 46 . Third, APOE-lipoprotein particles secreted by astrocytes have higher affinity for LDLR than for LRP1 46 , whereas recombinant APOE 51 , APOEenriched lipoprotein particles 52 and CSF-isolated HDL particles 53 bind more avidly to LRP1 than to LDLR. The receptor-binding specificity of APOE is probably influenced by its conformation and lipidation state. For example, native APOE-containing β-VLDL is a ligand for LDLR but not LRP1. However, APOE enrichment, with either recombinant APOE or APOE extracted from native β-VLDL, converts these particles into 
PDAPP amyloid mouse model
A mouse model of AD in which a human APP transgene bearing the amyloidogenic V717f mutation is overexpressed under the control of the human platelet-derived growth factor-β chain gene promoter.
high-affinity ligands for LRP1 (Ref. 52) . Therefore, the inability of APOE on native β-VLDL to bind to LRP1 is not due to any permanent modification of APOE but rather to the absence of the APOE conformation that is generated at higher concentrations of APOE. It is possible that APOE-lipoprotein particles secreted by astrocytes recruit additional APOE molecules, perhaps ones bound to heparan sulfate proteoglycan (HSPG), before being transported to the CSF or binding to LRP1 at the neuronal surface.
APOE receptors in neuronal signalling
In addition to transporting ligands to cells, APOE receptors mediate cellular signalling by binding to various extracellular ligands and intracellular adaptor proteins 17 . The best-characterized signalling pathway is triggered by reelin and mediated by APOER2 and VLDLR 17 . Reelin signalling is crucial for neuronal migration 39 , dendritic spine development 54 and synaptic plasticity 55, 56 . Although biochemical evidence suggests that APOE interferes with reelin binding to APOE receptors 57 , the in vivo significance of a relationship between reelin and APOE is not clear. In primary neurons, APOE isoforms differentially affect several signalling cascades through APOE receptors, causing increased phosphorylation of disabled 1, activation of the extracellular-signal-regulated kinase 1 (ERK1)-ERK2 pathway and inhibition of the c-JuN N-terminal kinase 1 (JNK1)-JNK2 pathway 58 . APOE4 but not APOE3 significantly increases resting Ca 2+ levels, Ca 2+ response to NMDA (N-methyl-d-aspartate) and neurotoxicity in a manner that depends on the function of LRP1 (Ref. 59) . APOE3-lipoprotein affords greater protection from apoptosis than APOE4-lipoprotein through LRP1-mediated signalling that involves activating protein kinase Cδ (PKCδ) and inactivating glycogen synthase kinase 3β (GSK3β) 60 . The isoform-specific signalling function of APOE and its potential in vivo relevance to AD pathogenesis require further investigation.
APOE receptors, APP trafficking and Aβ production
Aβ accumulation, oligomerization and deposition in the brain are central events in the pathogenesis of AD. The Aβ level in the brain is the net balance of Aβ production and clearance. Accordingly, Aβ accumulation in AD brains could reflect overproduction, inefficient clearance or both. Mounting evidence demonstrates that APOE and APOE receptors play important parts in both processes.
Several APOE receptors interact with APP and modulate its trafficking and processing to Aβ. Kounnas et al. 61 first demonstrated that LRP1 binds to soluble APP that contains the Kunitz-type protease inhibitor (KPI) domains (APP751 and APP770) extracellularly, and mediates its cellular catabolism. Further studies demonstrated that LRP1 also interacts with the neuronal isoform of APP that lacks the KPI domain (APP695). Two different phosphotyrosine-binding (PTB) domains in the adaptor protein FE65 (also known as APBB1) bind to the NPxy motifs in APP and LRP1, and thus FE65 bridges these two membrane proteins intracellularly 62, 63 . The extracellular and intracellular interactions between APP and LRP1 were confirmed in living cells by fluorescence resonance energy transfer (FRET) measurements 64 . The consequence of APP and LRP1 interaction is accelerated APP endocytic trafficking and processing to Aβ 65 , due to the fast rate of LRP1 endocytosis compared with that of APP 66 (fIG. 3) . Because the β-secretase BACE1 is abundantly present and active in acidic endosomes 67 , increased distribution of APP in endosomes leads to increased amyloidogenic processing and Aβ production. The role of LRP1 in facilitating APP processing to Aβ is also supported by evidence that overexpression of a functional LRP1 minireceptor in neurons in the PDAPP amyloid mouse model causes an age-dependent increase in soluble brain Aβ 68 . Because LRP1 also has a role in Aβ clearance (see below), no significant changes in either total Aβ or plaque burden were detected. APOE isoforms also differentially regulate APP processing to Aβ through a mechanism that depends on LRP1 function. In a neuronal cell line that overexpresses APP, APOE4 has been shown to increase Aβ production to a greater Box 1 | LRP1 undergoes APP/Notch-like proteolytic processing and shedding
In addition to undergoing furin cleavage in the trans-Golgi network (TGN) during its biogenesis, mature LDLR-related protein 1 (LRP1) is also subjected to several sequential proteolytic events that resemble amyloid precursor protein (APP)/Notch processing (see the figure) . First, it undergoes ectodomain shedding, which is mediated by metalloproteinases (MMPs) acting at a region close to the membrane, to release a soluble form of LRP1 (sLRP1) that can bind to ligands (ligand-binding domains are shown in red) 146, 147 . This ectodomain shedding occurs under physiological conditions, as evidenced by the abundant sLRP1 in human plasma 146, 148 . Second, LRP1 associates with the b-secretase BACE1 in lipid rafts and is a substrate for it 149 . Third, LRP1 can be cleaved at an intramembrane site by the γ-secretase 150 to release an LRP1 intracellular domain (LICD), which can regulate gene transcription 151, 152 . The major enzyme(s) responsible for LRP1 shedding and the extent, if any, of altered LRP1 processing in Alzheimer's disease brains remain unknown. Furthermore, how these processing events and their cleavage products affect LRP1's cellular function is not clear. Other low-density lipoprotein receptor (LDLR) family members, such as APOE receptor 2 (Ref. 153) , undergo similar proteolytic processing, but the mechanisms and significance of these processing events are also poorly understood. Nature Reviews | Neuroscience Three other APOE receptors also interact with APP and regulate its trafficking and processing to Aβ (fIG. 3) . LRP1B, owing to its slow rate of endocytosis, contributes to retaining APP at the cell surface and reduces its processing to Aβ 38 . APOER2 either decreases or increases Aβ production depending on the experimental conditions. In the presence of F-spondin, which bridges the extracellular interaction between APP and APOER2, the slow rate of APOER2 endocytosis inhibits APP endocytic trafficking and reduces Aβ production 70 . However, in the absence of common ligands, APOER2 increases the distribution of APP into lipid rafts and APP processing to Aβ. A third APOE receptor that modulates APP trafficking and processing to Aβ is SORLA. Expression of SORLA is significantly reduced in AD brains 71 , and overexpression of SORLA in neurons shifts APP distribution to the Golgi compartment and decreases its processing to Aβ 72 . Importantly, a deletion of the Sorl1 gene in mice increases the concentration of Aβ in the brain 72 . More direct evidence linking SORLA to AD comes from a recent study which demonstrated that inherited variants in the SORL1 gene are associated with LOAD 73 . whether APOE isoforms have roles in SORLA's regulation of APP trafficking and processing is not known.
APOE receptors in Aβ clearance and aggregation
It is widely believed that impaired Aβ clearance is a major pathogenic event for LOAD. Aβ has a relatively short half-life in the brain. using in vivo microdialysis and a γ-secretase inhibitor, it has been shown that Aβ has a half-life of ∼2 h and ∼4 h in young and aged mice, respectively 74 . In human brains the Aβ clearance rate is 8.3% per hour 75 , indicating that Aβ is actively and efficiently cleared from the brain.
There are two major pathways by which Aβ is cleared from the brain: receptor-mediated clearance by cells in the brain parenchyma (microglia, astrocytes and neurons), along the interstitial fluid drainage pathway or through the blood-brain barrier (BBB); and through endopeptidase-mediated proteolytic degradation (fIG. 4) . Receptor-mediated clearance of Aβ in the brain is likely to be mediated by the APOE receptors LRP1, LDLR and VLDLR, which are widely expressed in neurons, astrocytes and microglia of the brain parenchyma, as well as in endothelial cells, astrocytes and smooth muscle cells at the BBB and cerebral arteries. APOE as well as LRP1 and several other LRP1 ligands (for example, α 2 -macroglobulin and lactoferrin) are present in amyloid plaques 49 . These receptors can bind Aβ directly 76 or indirectly through Aβ chaperones. APOE is the bestcharacterized Aβ chaperone. APOE immunoreactivity is found in amyloid plaques 6, 49 , suggesting that APOE interacts with Aβ directly in AD brains. The region of APOE that is responsible for Aβ binding is in the C-terminal domain, overlapping with the lipid-binding region 77, 78 . This suggests that the lipophilic Aβ peptide associates with APOE in a process that is analogous to lipid binding. Indeed, Aβ binding to APOE compromises its lipid-binding function 78 . Furthermore, Aβ peptides differentially modulate the binding of different APOE isoforms to APOE receptors 79, 80 . These results demonstrate that Aβ peptides can interfere with the normal function of APOE in brain lipid metabolism and thus contribute to AD pathogenesis. APOE3-lipoprotein binds to Aβ with higher affinity than APOE4-lipoprotein 81 . Accordingly, APOE3 clears Aβ through APOE receptors on the cell surface more efficiently than APOE4. Indeed, several studies using different amyloid mouse models expressing either human APOE3 or human APOE4 demonstrated that APOE3-expressing mice develop fewer amyloid plaques than APOE4-expressing mice [82] [83] [84] . Post-mortem studies have demonstrated increased amyloid plaque load in the brains of carriers of the ε4 allele for both sporadic 85 and genetic AD cases 86 , and this notion has been confirmed by positron Figure 3 | APP processing pathways regulated by low-density lipoprotein receptor family members and APoe. Newly synthesized amyloid precursor protein (APP) traffics through the secretory pathway to the plasma membrane, where it is primarily cleaved by the α-secretase in the non-amyloidogenic pathway to produce a minimally toxic peptide called P3. When APP is internalized through the clathrin-mediated pathway it is delivered to endosomes, where it is cleaved first by the β-secretase BACE1 and then by the γ-secretase to generate highly toxic amyloid-β (Aβ). Although most Aβ peptides are secreted to the extracellular space, some can aggregate in the late endosomes or lysosomes and contribute to intraneuronal Aβ accumulation. The fast endocytosis of LDLR-related protein 1 (LRP1) enhances APP endocytosis and processing to Aβ, whereas the slow endocytosis of LRP1B and APOE receptor 2 (APOER2; also known as LRP8) contributes to retaining APP at the cell surface and promotes non-amyloidogenic processing. sortilin-related receptor with A-type repeats (sORLA; also known as sORL1 and LR11) probably shuttles APP to the Golgi compartments and reduces its processing by β-secretase in the early endosomes, thus decreasing Aβ production. Apolipoprotein E4 (APOE4) promotes APP amyloidogenic processing in a manner that depends on LRP1 function. APP's intracellular domain (AICD), a product of both non-amyloidgenic and amyloidgenic processing, interacts with FE65 (also known as APBB1) and TIP60 (also known as KAT5) and regulates gene transcription in the nucleus. sAPP, soluble APP. 
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PDGF-APP Sw,Ind amyloid mouse model
A mouse model of AD in which a human APP transgene bearing the amyloidogenic V717f, K670N and M671L mutations is overexpressed under the control of the human platelet-derived growth factor-β chain gene promoter.
Tg2576 amyloid mouse model
A mouse model of AD in which a human APP transgene bearing the amyloidogenic K670N and M671L mutations is overexpressed under the control of the hamster prion protein gene promoter.
emission tomography imaging studies from 'cognitively normal' controls 87 . Interestingly, a recent study showed that Aβ binding to APOE4 redirects its clearance from LRP1 to VLDLR, which internalizes Aβ-APOE4 complexes at the BBB more slowly than LRP1 (Ref. 88) . By contrast, Aβ-APOE2 and Aβ-APOE3 complexes are cleared at the BBB through both VLDLR and LRP1 at a substantially faster rate than Aβ-APOE4 complexes. The importance of APOE receptors in brain Aβ clearance was demonstrated in the PDGf-APP sw,Ind amyloid mouse model, which has decreased APOE receptor expression due to a deletion of the chaperone RAP 89 . Recombinant RAP and LRP1 antibodies also reduce Aβ efflux from mouse brain 90 . The receptor-mediated clearance is, in principle, an efficient way of reducing brain Aβ, because most Aβ that is internalized by APOE receptors is delivered to lysosomes for degradation or transcytosed into the plasma (fIG. 4) . However, it is possible that receptor-mediated clearance of Aβ into neurons can lead to intraneuronal Aβ accumulation, which is toxic 91 . A portion of the Aβ that is internalized by neurons, particularly oligomeric Aβ42, accumulates in multivesicular bodies, late endosomes and lysosomes and contributes to lysosomal dysfunction and neuronal toxicity. By contrast, receptor-mediated internalization of Aβ by astrocytes 92 and microglia 93 is likely to represent a more functional pathway to clear and eventually degrade Aβ.
APOE4 is also associated with increased risk for CAA 94 . Interestingly, the Aβ40/Aβ42 ratio in cerebral vascular Aβ deposits exceeds that of senile plaques 95 . Therefore, an increased Aβ40/Aβ42 ratio can shift Aβ deposition from the brain parenchyma to the vascular wall, perhaps by increasing the solubility of Aβ and hence its diffusion to the vasculature. APOE4 alters the Aβ40/Aβ42 ratio and promotes the formation of CAA in the Tg2576 amyloid mouse model 96 . CAA is associated with eventual degeneration of smooth muscle cells, which express high levels of LRP1. It is possible that smooth muscle cells contribute significantly to receptormediated Aβ clearance in normal brains, but that when Aβ accumulates under pathological conditions such as those of AD it can exceed the capacity of this clearance pathway, resulting in local Aβ aggregation and toxicity to smooth muscle cells. Further studies are needed to test this hypothesis.
Aβ can also be removed from the brain by proteolytic degradation. Several Aβ-degrading enzymes have important roles in Aβ clearance 97, 98 . Most of these enzymes are produced by neurons or glia, but some are also expressed in the cerebral vasculature. Neprilysin (also known as membrane metalloendopeptidase) and insulin-degrading enzyme (IDE) are the two most extensively studied Aβ proteases that are expressed in both neurons and vascular cells. Reduced expression of these two enzymes in AD has been associated with the ε4 allele of APOE. Other Aβ-degrading enzymes include plasmin, endothelin-converting enzyme 1 (ECE1), ECE2, matrix metalloproteinase 2 (MMP2), MMP3, MMP9 and angiotensin-converting enzyme (ACE). The specific roles Amyloid-β (Aβ) accumulation in the brain parenchyma leads to the formation of Aβ oligomers and amyloid plaques, which are toxic to neurons, whereas its accumulation in the perivascular region leads to cerebral amyloid angiopathy (CAA), which disrupts vessel function and is associated with cerebral haemorrhage. Aβ has a relatively short half-life (t 1/2 ) in the brain: ~2-4 h in mice and ~8 h in humans. Major Aβ clearance pathways include receptor-mediated clearance by cells in the brain parenchyma (neurons and glia), along the interstitial fluid (IsF) drainage pathway and through the blood-brain barrier (BBB), and proteolytic degradation by endopeptidases. The comparative effects of apolipoprotein E3 (APOE3) and APOE4 are indicated. In all major cellular Aβ clearance pathways, LDLR-related protein 1 (LRP1) is involved and is likely to clear Aβ either directly or when Aβ binds to its chaperones, which are also LRP1 ligands (for example, APOE and α 2 -macroglobulin). Low-density lipoprotein receptor (LDLR) function in Aβ clearance is likely to involve Aβ-APOE complexes. Very low density lipoprotein receptor also has a role in the clearance of Aβ-APOE complexes at the BBB. IDE, insulin-degrading enzyme.
Protein prenylation and isoprenylation
The covalent attachment of hydrophobic prenyl or isoprenyl groups to a protein. These processes have roles in protein attachment to cell membranes and protein-protein interactions.
for each of these enzymes in AD pathogenesis are still unclear. Interestingly, APOE promotes Aβ degradation by neprilysin and IDE, with APOE3 functioning more efficiently than APOE4 (Ref. 99) . The mechanism that underlies this observation warrants further investigation.
APOE in Aβ-induced neurotoxicity
Aβ assemblies, particularly Aβ oligomers, are highly toxic to neurons. Synthetic Aβ42 oligomers inhibit the viability of cultured neurons 10-fold more than Aβ42 fibrils and 40-fold more than unaggregated peptides 100 . APOE4 augments Aβ42 oligomer-induced neurotoxicity to a larger extent than APOE3 (Ref. 101) . Aβ dimers from human AD brains 102 and Aβ dodecamers (also known as Aβ*56) from Tg2576 mouse brains 103 inhibit long-term potentiation (LTP) and memory in animal models, but it is not known whether these toxicities are further regulated by APOE. Recently, APOE4 and Aβ aggregates (the aggregation of which was induced by inhibiting neprilysin) were found to act synergistically to induce neurodegeneration in the mouse brain 104 . Because neurodegeneration was not reported in several amyloid mouse models expressing human APOE4, it is not clear why Aβ accumulation induced by inhibiting neprilysin caused neurodegeneration whereas Aβ accumulation induced by overproduction of mutant APP did not. Studies of the potential roles of soluble APPs and the APP intracellular domain (AICD) 105 , which are more abundant in APP-overexpressing mice, might explain this difference.
APOE, tau and mitochondrial dysfunction
Hyperphosphorylated microtubule-associated protein tau (MAPT; also known as tau) is toxic to neurons and is the major component of neurofibrillary tangles. Tau is essential for Aβ-and excitotoxin-induced neuronal dysfunction: reducing endogenous tau blocks Aβ-induced cognitive impairments in the PDGF-APP Sw,Ind amyloid mouse model 106 . Transgenic overexpression of APOE4 in neurons but not in astrocytes increases tau phosphorylation in mice 107, 108 , suggesting a neuron-specific effect of APOE4 on tau phosphorylation. The pathophysiological significance of this pathway is not clear, as APOE is generally produced by astrocytes and microglia, not neurons. However, APOE expression in neurons has been reported after injury 109 . Although APOE is not expressed in hippocampal neurons under normal conditions, neuronal injury induced by kainic acid upregulates APOE expression in neurons 110 . Therefore it is possible that, in stressed AD brains, abnormal APOE expression in neurons facilitates tau hyperphosphorylation.
Another question that remains to be solved is how APOE and tau, which are normally separated by the plasma or organelle membrane, come into physical contact. One hypothesis is that C-terminal-truncated fragments of APOE, which have been detected in both human AD brains and a mouse model of AD in which an APOE4 transgene is expressed in neurons, enter the cytosol and interact directly with tau 108 . Alternatively, APOE isoforms might differentially regulate APOE receptor-mediated signalling cascades that in turn modify the function of tau kinases and phosphatases.
The receptor-and lipid-binding regions of APOE4 fragments act together to cause mitochondrial dysfunction and neurotoxicity 111 . using a cultured neuronal cell line, it was shown that the receptor-binding region of APOE4 C-terminal truncated fragments is required for their escape from the secretory pathway, and the lipidbinding region mediates interaction with mitochondria, leading to mitochondrial dysfunction. The in vivo relevance of this APOE4-mediated toxic pathway requires further investigation 112 .
APOE and APOE receptors in brain lipid transport
The primary function of APOE in the brain is to transport cholesterol, mainly from astrocytes to neurons. Cholesterol is an essential component of membranes and myelin sheaths and is crucial for synaptic integrity and neuronal function 113 . The reduced synthesis and greater need for cholesterol in neurons in adult brains mean that active cholesterol transport is needed to support synaptic functions and repair. Cholesterol associated with APOE-lipoprotein particles that are secreted by astrocytes is essential for the formation of mature synapses in vitro, through a mechanism that requires functional APOE receptors 114 (fIG. 5) . Interestingly, an association between cholesterol metabolism and the risk of AD has been proposed 115 . In humans, early studies indicated that the use of statins, which inhibit cholesterol synthesis, is associated with a significant decrease in AD prevalence; however, several recent retrospective studies do not support such a conclusion 115 . Because statins also exert other pleiotropic effects, including regulation of gene expression and protein prenylation and isoprenylation, the specific effects of statins on AD pathology in different model systems are likely to be influenced by various biological and pathological factors, such as the efficiency of blood flow to the brain and the presence of other disease states, including hypertension, diabetes and hypercholesterolaemia. At the cellular level, the effect of cholesterol on the amyloidogenic processing of APP to Aβ remains controversial 116, 117 . Cholesterol and statins clearly modulate APP processing in vitro and in vivo 118, 119 . Many of the effects of cholesterol on APP processing relate to the important role of cholesterol in lipid rafts, where APP processing by β-and γ-secretase cleavage is favoured 119, 120 . Cholesterol levels in AD brains are lower than in healthy brains 121, 122 . Interestingly, APOE4 knock-in mice have lower than normal brain cholesterol concentrations even though their peripheral cholesterol levels are increased 123 . This finding confirms that brain APOElipoprotein metabolism is distinct from that in the plasma. Although the exact functional differences among the three APOE isoforms in brain cholesterol metabolism are still not clear, there is some evidence that APOE4 might be less efficient than APOE3 in transporting brain cholesterol 50 . APOE4 is also less efficient than APOE3 in promoting cholesterol efflux from both neurons and astrocytes 124 . using cultured astrocytes from APOE targeted replacement (TR) mice, it was shown that fewer APOE3 than Nature Reviews | Neuroscience APOE4 molecules are needed to generate lipid particles of a given size 125 . This suggests that APOE3-expressing astrocytes can supply more cholesterol to neurons than APOE4-expressing astrocytes 125 . Despite these interesting observations, the roles of the different APOE isoforms in brain cholesterol metabolism require further investigation. The structural differences among APOE isoforms that determine their lipid-and receptor-binding specificities in the brain might account for their differences in modulating brain cholesterol metabolism. It is important to note that there are likely to be LRP1-mediated cholesterol transport mechanisms in the brain that are independent of APOE, because LRP1-deficiency in the brain but not APOE-deficiency leads to decreased brain cholesterol levels. Other LRP1 ligands such as lipoprotein lipase might also play a part. Alternatively, LRP1 might serve as a cholesterol sensor that influences cholesterol synthesis and/or intracellular transport.
In addition to cholesterol, APOE mediates the transport of other brain lipids, some of which are not produced in astrocytes. For example, sulfatide, an oligodendrocytesynthesized lipid that is crucial for neuronal spine and myelin sheath integrity, is actively transported by an APOE-and LRP1-dependent mechanism 126 . It is possible that APOE-lipoprotein particles are modified by myelinassociated lipids before being transported into neurons.
Interestingly, sulfatide is a potential biomarker for AD diagnosis as its levels are decreased in AD brains 126 . APOE, synaptic plasticity and spine integrity Synaptic failure is an early pathological feature of AD 127 . APOE-and APOE receptor-mediated lipid redistribution and signalling play important parts in synaptic integrity and plasticity. Increasing evidence demonstrates that APOE isoforms differentially regulate synaptic plasticity and repair. Human APOe4 TR mice display synaptic deficits in the absence of neuropathology 128 . LTP in the hippocampus of APOE4 TR mice is also significantly impaired compared with APOE3 TR mice and wild-type mice 129 . APOE expression is upregulated in rat brains after ischaemia 130 and in injured neurons upon kainic acid treatment 110 . The primary function of injury-induced APOE expression is probably to redistribute lipids and strengthen APOE-mediated signalling for neuronal and synaptic repairs. using β-VLDL enriched with APOE isoforms or APOE-containing HDL isolated from the CSF, it was shown that APOE3 increases neurite outgrowth whereas APOE4 either decreases outgrowth or has no effect 53, 131, 132 . Similarly, APOE3-containing lipoprotein particles are more effective than APOE4 particles in protecting CNS neurons from apoptosis 60 . Collectively, these studies indicate that APOE4 is less effective than APOE3 in maintaining and repairing synapses and neurons, which may explain why under certain neuronal injury conditions, such as severe head trauma and stroke, individuals with APOE4 tend to have a poorer outcome. It is possible that LOAD is a result of cumulative injury from Aβ and other neuronal stresses, such as oxidation and inflammation, and that APOE4 is less effective in maintaining and repairing injured synapses and neurons.
The APOE isoforms also differentially regulate dendritic spines during aging. APOE3-expressing and wild-type mice have a higher density of dendritic spines than APOE4-expressing and APOE-knockout mice at 1-2 years of age but not at 3 weeks of age 133 . This agedependent difference suggests that the effects of the APOE isoforms on neuronal integrity might relate to the increased risk of dementia in aged individuals that express APOE4. In patients with AD and in aged controls the APOE4 dose inversely correlates with dendritic spine density 133 . Interestingly, APOE2 overexpression ameliorates dendritic spine loss in Tg2576 amyloid model mice, suggesting that the APOE isoforms functionally interact with Aβ to regulate neuronal integrity 134 . Moreover, a recent in vitro study showed that rosiglitazone, a peroxisome proliferator-activated receptor-γ (PPARγ) agonist, increases dendritic spine density and rescues spine loss caused by APOE4 in primary neurons 135 . whether the different effects of the APOE isoforms on dendritic spine density relate to APOE-and APOE receptor-mediated lipid metabolism, signalling and/or synaptic plasticity and repair is not currently clear.
APOE and APOE receptors as therapeutic targets
Most therapeutic approaches to AD have been designed to reduce Aβ production or aggregation or to promote its clearance. Because APOE and the APOE receptors have crucial roles in both Aβ-dependent and Aβ-independent AD pathogenic pathways, it is logical to also consider strategies that regulate their expression and functions (TABLe 1) . As APOE4 is a strong risk factor for AD, whereas APOE3 is not, one attractive approach is to convert APOE4 to an APOE3-like molecule. The domain interaction that exists in APOE4 but not APOE3 seems to be responsible for most of the APOE4-associated neuropathology and provides a possible target. Indeed, several molecules that can disrupt the APOE4 domain interaction have been identified. Among these, GIND-25, a disulfonate, and GIND-105, a monosulfoalkyl, decrease Aβ production induced by APOE4 such that it reaches a level similar to that induced by APOE3 (Ref. 112) . whether these compounds can diminish APOE4's toxic functions in animals or humans in vivo is currently unknown.
Another potential strategy is to regulate APOE expression levels in the brain. However, this strategy requires careful consideration as to whether APOE4 effects in AD brains are caused by loss of protection, gain of toxicity or both. It has been shown that the promoter polymorphisms of the APOE gene may lead to changes in APOE expression levels by altering transcription of the APOE gene 136 . Therefore, regulating APOE promoter function might be one strategy to alter APOE expression. Compounds that alter brain APOE expression might also be identified through screening. using an APOE4-specific immunoassay, a recent study demonstrated that APOE4 has a faster turnover and lower steady-state concentration in APOE4 TR mice than in APOE3 TR mice 137 , suggesting that low total levels of APOE4 might directly contribute to AD pathogenesis, perhaps owing to reduced APOE function in lipid metabolism, synaptic repair and Aβ clearance. Therefore, increasing the expression of APOE in all APOE genotypes might prevent or slow the progression of AD. However, increasing the expression of APOE, particularly APOE4, may also generate deleterious effects such as slowing Aβ clearance through the BBB 88 and augmenting Aβ neurotoxicity 101 . The specific effects of altering APOE expression on AD pathogenesis will probably depend on the APOE isoforms, the stage of the disease and the presence of other pathophysiological conditions. Liver X receptors (LXRs) are oxysterol receptors that act as transcription factors to regulate cholesterol homeostasis. In the brain, LXRs upregulate APOE and ABCA1, thereby promoting cholesterol efflux in neurons and glia 138 . In the Tg2576 amyloid mouse model, LXR agonists facilitate the clearance of Aβ42 and reverse the contextual memory deficit 139 . Thus, LXR agonists may represent an important therapeutic approach to AD. Another related approach is to identify APOE-mimetic peptides that perform APOE-related functions and cross the BBB 140 . In this regard, APOE-mimetic peptides suppress glial inflammation and protect neurons from injury 141, 142 . Because these APOE-mimetic peptides do not contain lipid-binding domains, their exact mechanism of action is currently unknown. Nonetheless, their promising effects make them strong candidates for AD therapy.
Because APOE is essential for amyloid deposition in mice 143 , disrupting the APOE-Aβ interaction could be another therapeutic approach. An Aβ12-28 synthetic peptide, which is homologous to the APOE-binding site on the full-length Aβ, BBB permeable and non-toxic, reduced the total brain Aβ levels, Aβ plaques and CAA burden, and improved memory performance in two amyloid mouse models 144 . This suggests that inhibiting the APOE-Aβ interaction in vivo might decrease total brain Aβ.
APOE receptors are also potential targets for AD therapy. LRP1 and LDLR have crucial roles in brain APOE-lipoprotein metabolism and Aβ clearance. Because the LRP1 level is decreased in AD brains 145 , it will be interesting to test whether restoring LRP1 expression in AD brains augments Aβ clearance and reduces AD pathology. APOER2 and VLDLR are both implicated in reelin-APOE signalling, which is important for synaptic repair and plasticity. Therefore, compounds that upregulate their expression and/or function might be attractive therapeutic approaches. One caveat, however, is that upregulating APOE receptor expression and/or function might increase the risk of other diseases, such as cancer. Other APOE-or APOE receptor-related strategies include reducing APOE fragmentation, which might block interactions between APOE fragments and tangles or mitochondria; preserving brain APOE levels by increasing the APOE recycling efficiency; and blocking the interaction between APP and certain APOE receptors (such as LRP1) that promotes APP processing. Strategic combinations of modulations of the Aβ and APOE pathways are highly promising avenues of investigation for combating AD.
Perspectives APOE4 is a strong risk factor for LOAD. An emerging body of data has identified multiple pathways that could explain the pathogenic nature of APOE4. These include Aβ production, Aβ clearance, Aβ fibrillization, tangle formation, cholesterol homeostasis, synaptic plasticity and repair, and neuronal toxicity (fIG. 6) . From these, we must identify the pathways that are most relevant to AD pathogenesis and those that present targets with tractable efficacy for AD therapy. Greater understanding of the differential expression and function of the APOE isoforms has been facilitated by new animal models, including human APOE isoform TR mice and mice that express humanized APOE in an APOE-knockout background. Inducible expression of the APOE isoforms in aged animals should further clarify the roles of the APOE isoforms in aging brains. Furthermore, the relationship between brain APOE-mediated cholesterol and lipid metabolism and APOE-mediated Aβ and tau pathology should be studied in vivo. Finally, the functional relationship between the APOE isoforms and the multiple APOE receptors requires more in-depth investigation. Because the population of patients with AD and an APOE4 genotype is much larger than the population of patients with early-onset AD, therapies based on using APOE or APOE receptors as targets might benefit more AD patients than other types of therapies and offer hope to those reaching old age. 
